GlassScriptPhysician profile
George Dmytrenko
NPI 1104833557
$999.97
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $140.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $85.13 | 2019 | |
| Biogen, INC. | $83.31 | 2019 | |
| Sunovion Pharmaceuticals INC. | $66.64 | 2019 | |
| Allergan, INC. | $65.03 | 2019 | |
| Genentech USA, INC. | $48.47 | 2019 | |
| Ge Healthcare | $45.52 | 2019 | |
| Amgen INC. | $43.78 | 2019 | |
| Avanir Pharmaceuticals, INC. | $41.03 | 2019 | |
| Eisai INC. | $37.65 | 2019 | |
| Alexion Pharmaceuticals, INC. | $33.21 | 2019 | |
| Acadia Pharmaceuticals INC | $32.46 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.09 | 2019 | |
| Portola Pharmaceuticals, LLC | $26.34 | 2019 | |
| Strongbridge US INC. | $26.25 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $23.41 | 2019 | |
| Emd Serono, INC. | $22.33 | 2019 | |
| Tanabe Pharma America, INC. | $21.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.61 | 2019 | |
| Akcea Therapeutics, INC. | $19.39 | 2019 | |
| Adamas Pharmaceuticals, INC. | $18.51 | 2019 | |
| Abbvie INC. | $17.11 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.58 | 2019 | |
| Assertio Therapeutics, INC. | $12.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.03 | 2019 | |
| Livanova USA, INC. | $11.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Dmytrenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.